Latest News on Pfizer Inc. (PFE) Stock

  • Pfizer (PFE) Reports Positive Phase III Results For Nerve-Pain Drug [December 19 2014 04:11 AM]
  • Pfizer (PFE) Reports Positive Phase III Results For Nerve-Pain Drug   Bidness ETC - 13 hours ago Pfizer Inc. (NYSE:PFE) yesterday announced positive results for its Phase III study evaluating pregabalin controlled-release (CR) treatment, marketed as Lyrica, as a treatment for postherpetic neuralgia, or pain due to nerve damage. Stock Update: Pfizer Inc. (NYSE:PFE) - Street Report  Pfi... Read more about this Pfizer Inc. (PFE) news
  • 3 Pharma Giants Growing Significantly Faster Than Pfizer, Inc. [December 19 2014 04:11 AM]
  • 3 Pharma Giants Growing Significantly Faster Than Pfizer, Inc.   Motley Fool - 13 hours ago The largest pharmaceutical company in the world, Pfizer (NYSE: PFE ) , is a fixture in a number of retirement portfolios, and it's a staple holding of income investors looking for exposure to the healthcare sector. Read more about this Pfizer Inc. (PFE) news


  • Pfizers Duchenne Muscular Dystrophy Drug in Phase II [December 18 2014 03:03 PM]
  • Pfizers Duchenne Muscular Dystrophy Drug in Phase II   Zacks.com - Dec 18, 2014 Pfizer Inc. (PFE - Analyst Report) enrolled the first patient in a multicenter phase II study on its experimental Duchenne muscular dystrophy (DMD) treatment, PF-06252616. Pfizer commences Phase 2 study in Duchenne Muscular Dystrophy - Seeking Alpha  Pfizer Initiates Phase 2 Study of PF-06252616 in Duchenn... Read more about this Pfizer Inc. (PFE) news


  • Pfizer, Inc. Invests in Growth... Literally [December 17 2014 04:56 AM]
  • Pfizer, Inc. Invests in Growth... Literally   Motley Fool - Dec 17, 2014 Pfizer Inc. (NYSE: PFE ) locked up commercial rights to Opko Health's (NYSE: OPK ) long-lasting human growth hormone in a deal worth hundreds of millions of dollars. Read more about this Pfizer Inc. (PFE) news
  • Pfizer Reports Top-Line Results From a Phase 3 Study Evaluating Pregabalin Controlled-Release Formulation as a Treatment for Patients With Postherpetic Neuralgia [December 18 2014 05:07 AM]
  • [at noodls] - NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) announced today top-line results from a double-blind Phase 3 study evaluating pregabalin controlled-release (CR) formulation in adult patients with postherpetic ... Read more about this Pfizer Inc. (PFE) news

Looking for Market Opportunties?


Today's Most Active Stocks
Today's Biggest Price % Gainers
Today's Biggest Price % Losers
Today's Unusual Rising Volume Stocks
Today's Unusual Falling Volume Stocks
Research Reports
Earning Calendar
ETF Center